title: Tafamidis.
abstract: In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.
authors.forename: Gerard
authors.initials: G
authors.lastname: Said
authors.forename: Seden
authors.initials: S
authors.lastname: Grippon
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D017772:Amyloid Neuropathies / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001583:Benzoxazoles / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D011228:Prealbumin / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D001583:Benzoxazoles; D011228:Prealbumin; C547076:tafamidis